In this Healio Video Perspective from Retina 2025, Ashkan M. Abbey, MD, discusses 1-year results from the phase 2 DAVIO 2 clinical trial investigating EYP-1901 in previously treated wet age-related ...

Regeneron Pharmaceuticals has announced results from the phase 3 QUASAR trial and its extension study of the phase 3 PULSAR ...

Lower rates of both progression of macular fibrosis and intravitreal aflibercept injections were found in those who used the ...

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib ...

Bayer seeks European approval of extended 6-month treatment interval for Eylea 8 mg to treat nAMD & diabetic macular edema: Berlin Tuesday, February 11, 2025, 10:00 Hrs [IST] Baye ...

In the trial, subjects treated with the Eylea HD 8mg injection every eight weeks showed non-inferior visual acuity gains.

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) results for EYLEA HD (aflibercept) Injection 8 mg in ...

On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court for the Northern District of West ...

D Molecular Therapeutics reported 52-week Phase 2b data for 4D-150 in wet AMD, showing sustained visual acuity improvements.

Regeneron Pharmaceuticals Inc. (REGN) announced encouraging outcomes from the Phase 3 QUASAR trial, which evaluated the efficacy of ...

In this Healio Video Perspective from Retina 2025, Ramiro Ribeiro, MD, PhD, of EyePoint Pharmaceuticals, discusses Duravyu, a vorolanib intravitreal insert. According to Ribeiro, in the DAVIO 2 trial, ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...